Bruce Peterson, M.D.

Area of Expertise: Lymphoma

Selected Publications

Glick JH, Young ML, Harrington D, Schilsky RL, Beck T, Neiman R, Fisher RI, Peterson BA, Oken MM.  MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: The 8-year results of the intergroup trial.  J Clin Oncol 1998; 16:  19-26.

Coleman M, Rafla S, Propert KJ, Glicksman A, Peterson B, Nissen N, Brunner K, Holland JF, Anderson JR, Gottlieb A, Kaufman T.  Augmented therapy of extensive Hodgkin's disease: radiation to known disease or prolongation of induction chemotherapy did not improve survival -- results of a Cancer and Leukemia Group B study.  Int J Radiation Oncology Biol Phys 1998; 41:  639-645.

Morrison VA and Peterson BA.  High-dose therapy and transplantation in non-Hodgkin's lymphoma.  Semin Oncol 1999; 26:  84-98.

Wasserman TH, Petroni GR, Millard F, Chung C, Barcos M, Johnson JL, Canellos GP, Peterson BA:  Chemotherapy (etoposide, vinblastine, and doxurubicin) (EVA) and subtotal nodal radiation for localized Hodgkin's disease with unfavorable prognostic features:  A phase II CALGB study (9051).  Cancer 1999; 86: 1590-1595.

Peterson BA:  Current treatment of follicular, low-grade lymphomas. Semin Oncol 1999; 26(5)(suppl.14): 2-11.

Grillo-Lopez AJ, Cheson BD, Horning SJ, Peterson BA, Carter WD, Varns CL, Klippenstein DL, Shen CD.  Response criteria for NHL:  Importance of "normal: lymph node size and correlations with response rates.  Ann Oncol 2001; 11:  399-408.

Peterson BA.  Chemotherapy of hodgkin’s disease.  In:  Perry MC (ed.).  The Chemotherapy Source Book.  Williams and Williams:  Baltimore, MD, 2000.

Lichtman SM, Niedzwiecki D, Barcos M, Carlisle TL, Cooper MR, Johnson JL, Peterson BA.  Phase II study of Infusional Chemotherapy with Doxorubicin, Vincristine, and Etoposide Plus Cyclophosphamide and Prednisone (I-CHOPE) in Resistant Diffuse Aggressive Non-Hodgkin’s Lymphoma:  CALGB 9255.  Ann Oncol 2000; 11:  1141-1146.

Lester EP, Petroni GR, Barcos M, Johnson JL, Millard FE, Cooper MR, Omura GA, Frei E, III, Peterson BA.  Cyclophosphamide, Doxorubicin, Vincristine, Prednisone and Etoposide (CHOPE) for Advanced Stage Hodgkin’s Disease:  CALGB 8856.  Cancer Invest 2001; 19:  447-458.

Lichtman SM, Niedzwiecki D, Schilsky RL, Johnson HL, Perri RT, Sklar J, Barcos MP, Peterson BA.  High-dose Cyclophosphamide Plus Recombinant Human Granulocyte-colony Stimulating Factor (rhG-CSF) in the Treatment of Follicular, Low-grade Non-Hodgkin’s lymphoma:  CALGB 9150.  Leuk/Lymph 2001; 42: 1255-1264.

Bartlett NL, Petroni GR, Parker BA, Wagner ND, Gockerman JP, Omura GA, Canellos GP, Cooper MR, Johnson JL, Peterson BA.  Dose-escalated CHOPE Chemotherapy for Diffuse Lymphomas:  CALGB 8852/8854.  Cancer 2001; 92: 20717.

Lee EJ, Petroni GR, Freter CR, Johnson JL, Barcos M, Frizzera G, Bloomfield CD, Schiffer CA, Peterson BA.  Brief Duration High Intensity Chemotherapy for Patients with Small Noncleaved Cell Lymphoma or FAB L3 Acute Lymphocytic Leukemia.  Results of CALGB 9251.  J Clin Oncol 2001; 19: 4014-4022.

Press OW, LeBlanc M, Lichter AS, Grogan TM, Unger JM, Wasserman TH, Gaynor ER, Peterson BA, Miller TP, Fisher RI.  A Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA-IIA Hodgkin’s disease.  J Clin Oncol 2001; 19: 4238-4244.

Lichtman SM, Petroni G, Schilsky RL, Johnson JL, Perri RT, Niedzwiecki D, Sklar J, Barcos M, Peterson BA.  High dose cyclophosphamide plus recombinant human granulocyte-colony stimulating factor (rG-CSF) in the treatment of follicular, low grade non-Hodgkin's lymphoma: CALGB 9150.  Leuk Lymphoma 2001; 42:1255-1264.

Peterson BA, Petroni GR, Frizzera G, Barcos M, Bloomfield CD, Nissen NI, Hurd DD, Henderson ES, Sartiano GP, Johnson JL, Holland JF, Gottlieb AJ.  Prolonged single-agent versus combination chemotherapy in indolent follicular lymphomas: A study of the cancer and leukemia group B.  J Clin Oncol 2003; 21:5-15.

Duggan DB, Petroni GR, Johnson JL, Glick JH, Fisher RI, Connors JM, Canellos GP, Peterson BA.  Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: Report of an intergroup trial.  J Clin Oncol 2003; 21:607-614.

Rizzieri DA, Johnson JL, Niedzwiecki D, Lee EJ, Vardiman JW, Powell BL, Barcos M, Bloomfield CD, Schiffer CA, Peterson BA, Canellos GP, Larson RA.  Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma: Final results of Cancer and Leukemia Group B Study 9251.  Cancer 2004; 100:1438-1448.

Blaes AH, Peterson BA, Bartlett N, Dunn DL, Morrison VA. Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation: results of a phase II trial. Cancer. 2005; 104:1661-7 (Review).

Aslan DL, Peterson BA, Long-Tsai M, Eastlund T. Early-onset autoimmune hemolytic anemia after cladribine therapy for Waldenstrom's macroglobulinemia. Transfusion. 2006; 46:90-4.

Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB, Dakhil SR, Woda B, Fisher RI, Peterson BA, Horning SJ. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006; 24:3121-7. PMID: 16754935

Blum KA, Johnson JL, Niedzwiecki D, Piro LD, Saven A, Peterson BA, Byrd JC, Cheson BD; Cancer and Leukemia Group B Study 9153. Prolonged follow-up after initial therapy with 2-chlorodeoxyadenosine in patients with indolent non-Hodgkin lymphoma: results of Cancer and Leukemia Group B Study 9153. Cancer. 2006; 107:2817-25. PMID: 17120198

Dham A, Peterson BA. Castleman disease. Curr Opin Hematol. 2007; 14:354-9. Review. PMID: 17534161

Peterson BA, Johnson J, Shipp MA, Barcos M, Gockerman JP, Canellos GP; Cancer and Leukemia Group B 9351.High dose CHOP: a phase II study of initial treatment in aggressive non-Hodgkin lymphoma. Cancer and Leukemia Group B 9351. Leuk Lymphoma. 2007; 48:870-80. PMID: 17487729

Langer C, Radmacher MD, Ruppert AS, Whitman SP, Paschka P, Mrózek K, Baldus CD, Vukosavljevic T, Liu CG, Ross ME, Powell BL, de la Chapelle A, Kolitz JE, Larson RA, Marcucci G, Bloomfield CD; Cancer and Leukemia Group B (CALGB). High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study. Blood. 2008; 111:5371-9. PMID: 18378853

Blaes AH, Santa-Cruz KS, Lee CK, Hui SK, Peterson BA. Necrotizing leukoencephalopathy following CHOP chemotherapy. Leuk Res. 2008; 32:1611-4. PMID: 18378307

Bartlett NL, Johnson JL, Wagner-Johnston N, Ratain MJ, Peterson BA; For the Cancer and Leukemia Group B. Phase II study of 9-aminocamptothecin in previously treated lymphomas: results of Cancer and Leukemia Group B 9551. Cancer Chemother Pharmacol. 2008 Jul 23. PMID: 18648813

Jacobi N, Rogers TB, Peterson BA. Prognostic factors in follicular lymphoma: a single institution study. Oncol Rep. 2008; 20:185-93. PMID: 18575736

Cioc AM, Vanderwerf SM, Peterson BA, Robu VG, Forster CL, Pambuccian SE. Rituximab-induced changes in hematolymphoid tissues found at autopsy. Am J Clin Pathol. 2008; 130:604-12. PMID: 18794054

Meyerhardt JA, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, Nelson H, Whittom R, Hantel A, Thomas J, Fuchs CS; Cancer and Leukemia Group B 89803. Impact of body mass index and weight change after treatment on cancer recurrence and survival in patients with stage III colon cancer: findings from Cancer and Leukemia Group B 89803. J Clin Oncol. 2008; 26:4109-15. PMID: 18757324